Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Introduction both symptomatic and asymptomatic SARS-CoV-2 infections–coined
Coronavirus disease 2019 (COVID-19)–have been linked to a higher risk of cardiovascular …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Background: COVID-19 (coronavirus disease 2019) is associated with heightened risks of
venous and arterial thrombosis and hospitalization due to respiratory failure. To assess …

Background COVID-19 progression is associated with an increased risk of arterial and
venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the …

Based on emerging evidence from the COVID-19 pandemic, the International Society on
Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 …

Millions of people worldwide have chronic kidney disease (CKD). Affected patients are at
high risk for cardiovascular (CV) disease for several reasons. Among various comorbidities …

COVID-19: Hypercoagulability - UpToDate Wolters Kluwer UpToDate English Why
UpToDate? Product Editorial Subscription Options Subscribe Sign in Learn how UpToDate …

Objective Literature supports associations between common respiratory tract infections
(RTIs) and risk of cardiovascular diseases, yet the importance of RTIs for cardiovascular risk …

Recent publications have questioned the efficacy of using therapeutic or intermediate doses
of low molecular weight heparin (LMWH) in COVID-19 patients, especially in the most …